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ABSTRACT 
NEUROPSYCHIATRIC FEATURES OF PARKINSONIAN TAUOPATHIES 
AND ALPHA-SYNUCLEINOPA THIES 
Megan R. Thompson 
November 24, 2008 
The goal of this thesis is to determine if neuropsychiatric features can differentiate 
parkinsonian patients with: tauopathies from those with alpha-synucleinopathies and 
explore caregiver distress. Three hundred and four patients (62 with tauopathies and 242 
with alpha-synucleinopathies) diagnosed according to published diagnostic criteria were 
evaluated using the Neuropsychiatric Inventory (NPI), Mini-Mental State Examination 
(MMSE), and Unified Parkinson's Disease Rating Scale (UPDRS). To control for 
between-group differences a subsample of235 patients were analyzed. Patients with 
tauopathies had significantly higher NPI total scores, more apathy, less hallucinations, 
lower MMSE scores and higher UPDRS scores than those with alpha-synucleinopathies. 
Hallucinations and delusions were not related to levodopa or dopamine agonist daily 
doses, but increased age was associated with these disturbances. There were moderate 
correlations between caregiver distress and severity of neuropsychiatric disturbances. 
Despite between-group neuropsychiatric differences at early stages, the symptom overlap 
does not allow to classify patients with these two proteinopathies. 
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INTRODUCTION 
The underlying abnormal accumulation of proteins in the brain among the different 
parkinsonian disorders leads to their molecular classification as tauopathies and alpha-
synucleinopathies (l, 2). Tauopathies include progressive supranuclear palsy (PSP) and 
corticobasal degeneration (CBD) (l). In both PSP and CBD tau accumulates as 
neurofibrillary tangles in neurons and threads in processes (3). In addition, tau deposits 
forming tufted astrocytes in PSP (3), and astrocytic plaques in CBD (3), are helpful 
features in their differentiation (7). Alpha-synucleinopathies include Parkinson's disease 
(PD), Parkinson's disease with dementia (PDD), dementia with Lewy bodies (DLB), and 
multiple system atrophy (MSA) (2). In PD and DLB, a-synuclein constitutes the major 
component of the Lewy bodies (2, 4), and in MSA it deposits as glial cellular inclusions 
(2,5). 
While this molecular classification has important implications for the 
pathogenesis of these disorders and the development of novel therapeutic approaches, its 
role in clinical practice has not been fully investigated. Clinically, tauopathies share 
features such as frontal dysfunction, oculomotor disturbances, and early pseudobulbar 
palsy (6, 7). Similarly, there is clinical overlap in alpha-synucleinopathies such as 
autonomic dysfunction, urinary, olfactory and REM sleep behavior disturbances (8-11). 
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This study seeks to determine if the neuropsychiatric features could be used to 
clinically distinguish a patient's disorder as a tauopathy or an alpha-synucleinopathy. To 
better characterize the behavioral aspects of parkinsonian patients with tauopathies and 
those with alpha-synucleinopathies, we compared their performance on the 
Neuropsychiatric Inventory (NPI), a tool with established validity and reliability 
(Cronbach's alpha = 0.88) (12). The NPI evaluates both the frequency and severity of 
delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, 
irritability, and abnormal motor behavior (e.g., pacing), as well as nighttime behaviors, 
appetite/eating changes, and caregiver distress (12-14). While the NPI and other 
instruments have been used to investigate various parkinsonian diseases individually, PD 
(15-20), PDD (15, 21), DLB (21-26), CBD (27, 28), and PSP (18, 28-30), no previous 
study has attempted to determine if there are neuropsychiatric differences between 
patients with tauopathies and those with alpha-synucleinopathies, or to examine the 
caregiver distress. 
Purpose and hypothesis 
The purpose of this research is to differentiate patients with tauopathies from those with 
alpha-synucleinopathies using the NPI scale. To do so, we examined the individual NPI 
domains in the two proteinopathy groups. Based on the literature (Table 1) and our 
clinical experience, we hypothesize that: (1) delusions and hallucinations are more 
common in alpha-synucleinopathies than tauopathies, (2) the presence ofthese 
disturbances is not related to the use of Parkinson's medications, and that (3) the 
caregiver distress will increase as the severity of neuropsychiatric disturbances increases. 
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METHODS 
This is an exploratory, cross-sectional, study that examined patients from 2003-2008 and 
included chart reviews. Three hundred and four patients, presenting as outpatients to the 
University of Louisville Movement Disorder Clinic were evaluated and diagnosed as 
having PD (n=143), PDD (n=12), DLB (n=36), MSA (n=51), PSP (n=49), and CBD 
(n=13), by three movement disorder specialists according to established criteria (PD (31), 
PDD (9), DLB (10), MSA (11), PSP (6), and CBD (7)). Exclusion criteria for all patients 
included history of alcohol or substance abuse, head trauma with loss of consciousness, 
and diagnosis of a psychiatric disorder preceding the onset of the current disease. All 
participating patients gave institutional IRB consent at the University of Louisville. The 
neuropsychiatric, cognitive, and motor assessments were usually conducted on the same 
day. 
Cognition was assessed with the Mini-Mental State Examination (MMSE) scale, a 
widely used tool to detect cognitive decline. The MMSE includes a series of questions 
examining orientation, registration, attention and calculation, recall, and language skills. 
The maximum total score is 30, which is considered a normal score. Patients presenting 
with cognitive problems will have a lower total score (32). 
Motor symptoms and signs were evaluated with the Unified Parkinson's Disease 
Rating Scale (UPDRS), which is divided into three sections: mentation, behavior, and 
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mood (UP DRS I), activities of daily living (UPDRS II), and motor abilities (UP DRS III). 
Patients' individual symptoms were evaluated by movement disorder specialists. The 
normal UPDRS score is zero and the total score will increase with enhanced motor 
disturbances (33). 
The NPI was administered as previously described (12-14) to the caregivers ofthe 
patients in a separate room. Briefly, screening questions are used to assess the behaviors, 
and if a positive response is obtained for one of the ten neuropsychiatric domains, then 
this aspect is further explored with scripted questions. Each behavior is individually 
scored by multiplying the frequency (1-4, occasionally to very frequently) by the severity 
(1-3, mild to marked), yielding a scale of 1 to 12. Although, this multiplication cannot 
lead to a variable measured on a continuum because some values are impossible to obtain 
(i.e., 5, 7 etc), the resulting distribution can still be analyzed with non-parametric tests. 
The total NPI score is the sum of all added subscale composite scores. The normal score 
is zero and will increase with the presence of neuropsychiatric symptoms. In some cases 
(11.8% of the sample) the NPI was administered more than once. We chose the most 
recent NPI scores to be used in the analyses. 
Two versions of the NPI were used to assess the neuropsychiatric disturbances of 
our patient sample. The new NPI version has two additional behavioral domains 
(nighttime behavior and appetite/eating change), although, neither of these domain scores 
are added to the total NPI score used in the analyses. Moreover, the new NPI scale 
includes a section for the assessment of the caregiver distress associated with the 
patients' neuropsychiatric characteristics. After the caregiver rated the severity and 
frequency of an NPI domain, the caregiver was further asked to rate the distress caused 
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by the presence of the individual domain (0-5, no distress to very severe or extreme 
distress). Once more, the caregiver distress score did not affect the NPI total score. 
Caregiver distress was recorded for 73 caregivers, including 15 caregivers of patients 
with tauopathies and 58 caregivers of patients with alpha-synucleinopathies. 
Exploratory univariate (frequencies, central tendency, and dispersion measures) 
and bivariate parametric and non-parametric statistical analyses (Mann-Whitney U and 
independent t tests, Pearson Chi-Square, Pearson r and Spearman's rho correlations) 
were applied as appropriate (34). Due to the distributions being skewed or non-linear, 
non-parametric tests were primarily used to explore the relationships between variables. 
Statistical tests were conducted with a 95% confidence level and significance was 
accepted at p < 0.05. 
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RESULTS 
Sample characteristics using NPI: 
Analyses of the full sample (N=304 patients) showed significant between-group 
differences in patient symptom duration and age at NPI evaluation. There was a mild but 
significant association between symptom duration and MMSE total (r = -0.23, P < .000). 
The patients with longer symptom duration scored lower on the MMSE, indicating 
cognitive decline. There were also significant associations between age at NPI evaluation 
and NPI total (r = 0.12, p = .032), MMSE total (r = -0.24, p < .000), and UPDRS total (r 
= 1.42, P =.013). These results suggest that the age at NPI evaluation is significantly 
associated with increased neuropsychiatric, cognitive, and motor disturbances. To adjust 
for the differences between the proteinopathy groups, the patients presenting symptoms 
for eight years or more were excluded from further data analyses. Additionally, three 
patients with alpha-synucleinopathies were excluded from further analyses because the 
NPI total score was an outlier, and would have skewed the results if they were maintained 
in the sample. With the new exclusion criteria, the resulting sample included 232 
patients: 59 patients with tauopathies (PSP (n = 47), and CBD (n = 12)) and 173 patients 
with alpha-synucleinopathies (PD (n = 101), PDD (n = 5), DLB (n = 31), MSA (n = 36)). 
For demographics see Table 2. There were no significant between-group differences in 
patient's age at NPI evaluation (U = 4288, P = .067), symptom duration (U = 5019, p = 
.848), and education level (U = 4627, P = .272). 
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NPI characteristics of the patients with tauopathies: 
The average total NPI score for the patients with tauopathies was 10.3 (range 0-34, SD = 
8.6) and apathy was the most frequent NPI domain present (67.8%) (Table 3). Apathetic 
disturbances were mild in severity 37.5%, moderate 47.5%, and severe 15% and the 
frequencies were occasional 7.5%, often 20%, frequent 22.5%, and very frequent 50%. In 
addition, depression (55.9%), nighttime behavior (51.3%), and appetite/eating changes 
(43.6%) were commonly reported for the patients with tauopathies. Less frequently, 
aberrant motor behaviors (8.5%), delusions (6.8%), hallucinations (3.4%), and euphoria 
(1.7%) were recorded. The highest average composite score was for apathy (4.0), 
followed by nighttime behavior (2.4), depression (2.1), and appetite/eating changes (2.0) 
(Table 3). 
NPI characteristics of the patients with alpha-synucleinopathies: 
The average NPI total score for the patients with alpha-synucleinopathies was 6.1 (range 
from 0-39, SD = 7.5) and depression (54.3%) was the most common neuropsychiatric 
symptom reported. Of the patients with alpha-synucleinopathies who exhibited 
depression, 70.2% were mild in severity, 26.6% moderate, and 3.2% severe. The 
frequency with which these disturbances occurred was occasional 41.5%, often 19.1 %, 
frequent 27.7%, and very frequent 11.7%. Other NPI domains commonly observed in this 
group were abnormal nighttime behaviors (41.5%) and apathy (40.5%). Disinhibition 
(8.7%), delusions (7.5%), and aberrant motor behaviors (5.8%) were less frequently 
reported. Euphoria was not exhibited by any patient with alpha-synucleinopathies. The 
highest NPI composite score in the patients with alpha-synucleinopathies was for 
nighttime disturbance (2.2) followed by depression (1.6), and apathy (1.6) (Table 3). 
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I 
Differentiating patients with tauopathies and alpha-syrucleinopathies based on 
neuropsychiatric, cognitive, and motor disturbances: i 
The patients with tauopathies scored significantly highet on the NPI (10.3 ± 8.6) than 
I 
patients with alpha-synucleinopathies (6.1 ± 7.5). Therel was a significant difference in 
I 
the total NPI score between the two proteinopathy grou~s (U = 3486, p < .000). 
! 
There were significant between-group differenc~s in the NPI apathy and 
hallucination scores. The patients with tauopathies wer~ more likely to express apathy 
(67.8%) than those with alpha-synucleinopathies (40.5*; t = 13.2, p < .000). On the 
I 
other hand, hallucinations were more frequent in the pa~ients with alpha-
I 
i 
synucleinopathies (17.9%) than those with tauopathies ~3.4%; 'X: = 7.6, p = .006). Of the 
! 




The MMSE score was significantly lower (U = i577, P = .001) for the patients 
with tauopathies (25.3 ± 5.9) than for the patients with ,lpha-synucleinopathies (27.0 ± 
! 
6.3). The patients with tauopathies scored significantly ~igher on the total UPDRS (54.2 
! 
± 18.5) compared to the patients with aIPha-SynUcleino~athies (37.5 ± 20.5), thus there 
was a significant difference between the UPDRS score tnd the two proteinopathy groups 
I 
(U = 2540, p < .000). On the UPDRS III, the patients Wfth tauopathies (29.3 ± 12.5) 
scored significantly higher (U = 3244, p < .000) than thf patients with alpha-
synuclcinopathies (21.8 ± 12.9). 
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Correlations between neuropsychiatric, cognitive, andimotor disturbances between the 
patients with tauopathies and alpha-synucleinopathie~: 
In the patients with tauopathies there are no significant associations between NPI total 
and MMSE total (r = -0.02, p = .895), NPI total and UPbRS total (r = -0.01, p = .925), 
and MMSE total and UPDRS total (rho = -0.13, p = .317). Results suggest no correlations 
between neuropsychiatric, cognitive, and motor disturb .. nces in the patients with 
tauopathies. 
In the patients with alpha-synucleinopathies thete was a moderate negative 
correlation between NPI total score and MMSE total score (r = -0.35, P < .000) also 
shown by the non-parametric test (rho = -0.39, p < .000). Results suggest there is a 
relationship between neuropsychiatric and cognitive disturbances in the patients with 
alpha-synucleinopathies. There was also a weak positiv~ correlation between the total 
NPI score and total UPDRS score (r = 0.18, p = .020) in the patients with alpha-
synucleinopathies. These results are the same when using the Spearman's rho correlation 
coefficient (rho = 0.26, P = .001). A weak, positive correlation between total NPI score 
and UPDRS III (rho= 0.20, p = .010) indicates that the neuropsychiatric disturbances 
increase with the higher occurrence of motor disturbanoes. 
In the group of patients with alpha-synucleinopathies, there was a weak negative 
correlation between total MMSE score and total UPDRS score (r = -0.29, p < .000; rho = 
.30, p<.OOO). There was also a weak negative correlation between total MMSE score and 
UPDRS III score (r = -0.21, p = .009; rho= -0.23, p = .003). These results suggest that as 
the cognition is more impaired, patients with alpha-synUcleinopathies also exhibited more 
motor disturbances. 
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Comparison of patients presenting with and without hallucinations and delusions: 
Levodopa daily dose was calculated according to published criteria (35). The average 
levodopa daily dose for the sample was 581 mg ± 684 mg (range 0 mg- 3417 mg). There 
were no significant differences in the daily levodopa dose between patients reporting 
hallucinations (715 mg ± 869 mg) and those without hallucinations (559 mg ± 648 mg; U 
= 2961, p = .360). Similarly, there were no significant differences in the daily levodopa 
dose between patients with delusions (657 mg ± 889 mg) and those without delusions 
(575 mg ± 667 mg; U = 1820, p = .976). The average daily dose of dopamine agonists 
including Pramipexole, Rotigotine, Ropinirole, and Pergolide, was 42 mg ± 110 mg 
(range 0 mg- 1106 mg). There was no significant difference between the daily dopamine 
agonist dose in the patients who reported hallucinations (81 mg ± 200 mg) compared to 
patients without hallucination disturbances (35 mg ± 86 mg; U = 2959, p = .256). There 
was no significant difference between the daily dopamine agonist dose in the patients 
who reported delusion disturbances (83 mg ± 145 mg) and those that did not (38 mg ± 
107 mg; U = 1451, P = .077). These findings suggest dopamine agents are not associated 
with the appearance of delusions or hallucinations in our total sample. 
There was a significant difference in the age at NPI evaluation between the 
patients who reported hallucinations (72 ± 8.6) and those who did not (68 ± 9.5; U = 
2382, p = 0.014). Additionally, the patients with hallucinations (69 ± 9.2) were 
significantly older at disease onset than the patients without hallucinations (66 ± 9.6; U = 
2408, P = 0.014). In the total sample, the number of patients presenting with hallucination 
disturbances increased symptomatically as they aged. 
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The age at NPI evaluation was greater (74 ± 7.4) for the patients with 
delusions than for the patients without delusions (69 ± 9.6). This difference was 
significant at 95% confidence level (U = 1284, p = 0.041). Moreover, there was a 
marginally significant difference (U = 1337, p = 0.065) in the age at disease onset 
between the patients with delusions (70 ± 7.7) and those without delusions (66 ± 9.7). 
Caregiver distress differences between the patients with tauopathies and alpha-
synucleinopathies: 
There were no significant differences between the distress total scores reported by the 
caregivers of the patients with tauopathies (7.9 ± 5.6) and alpha-synucleinopathies (5.7 ± 
5.3; t = 1.37, p = .176). These results are supported using a non-parametric test (U = 318, 
p = .107). 
In the patients with tauopathies, the mean caregiver distress score was 7.9 ± 5.6 
(range 0-5). The highest distress scores were in agitation (4.0), disinhibition (3.0), and 
apathy (2.7), although the agitation score is only representative of one caregiver and 
disinhibition of two caregivers (Table 4). Twenty percent of caregivers rated apathy 
disturbances as severely or very severely distressing. 
In the patients with alpha-synucleinopathies, the mean caregiver distress score 
was 5.7 ± 5.3 (range 0-5). The highest distress was with delusions (3.2), followed by 
apathy (2.4), and then agitation (2.3) (Table 4). Forty percent of caregivers reported the 
emotional distress caused by delusion as severely or very severely distressing. 
Caregiver distress and NPI domain severity: 
There was a moderate association between the depression caregiver distress score and 
depression severity (r = 0.55, p < .000), as well as with apathy severity (r = 0.39, p=.003). 
There was a moderate relationship between the anxiety caregiver distress score and 
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nighttime severity (r = 0.56, P = .006). Additionally, there was a moderate correlation 
between the apathy caregiver distress score and depression severity (r = 0.33, p = .044), 
and with apathy severity (r = 0.56, p < .000). These associations are sustained by non-
parametric tests as well. There was a moderate positive relationship between anxiety 
caregiver distress and depression severity (rho = 0.41, P = .047). 
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DISCUSSION 
According to our knowledge, the present study is the first to determine the 
neuropsychiatric differences between patients with tauopathies and alpha-
synucleinopathies using the NPI as a measuring tool. Additionally, this study is the first 
to evaluate caregiver distress using the NPI for patients with tauopathies or alpha-
synucleinopathies. Our study deducted several major findings. First, we found that at 
early stages patients with tauopathies exhibited significantly more apathy than those with 
alpha-synucleinopathies, and that patients with alpha-synucleinopathies reported 
significantly more hallucinations. Second, despite significant between-group differences 
in apathy and hallucinations, overlap and overall frequency of these specific 
neuropsychiatric symptoms do not allow to classify individual patients as having a 
specific proteinopathy. Third, at early disease stages the patients with tauopathies had 
more neuropsychiatric disturbances (higher total NPI), were more cognitively impaired 
(lower MMSE scores), and had more motor disturbances (higher UPDRS scores) than 
those with alpha-synucleinopathies. Fourth, while there were no associations between 
neuropsychiatric, cognitive, and motor symptoms in the group of patients with 
tauopathies, all three disturbances were correlated in the group of patients with alpha-
synucleinopathies. Fifth, we found that the hallucinations and delusions cannot be 
explained by the patient's totallevodopa daily dose or dopamine agonist daily dose, 
suggesting that these disturbances may be related to the accumulated 
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proteinopathy. Moreover, the patients with hallucinations and the patients with delusions 
were significantly older at NPI evaluation and older at disease onset, compared to 
patients who did not present these symptoms. Lastly, there were no significant 
differences in caregiver distress between the patients with tauopathies and those with 
alpha-synucleinopathies. When analyzing depression, anxiety, apathy, and nighttime 
behaviors only, caregiver distress correlated with the severity of these disturbances. 
Comparing the patients with tauopathies and alpha-synucleinopathies based on 
neuropsychiatric, cognitive, and motor disturbances: 
As expected, patients with tauopathies exhibited significantly more apathy, and those 
with alpha-synucleinopathies exhibited more hallucinations. Our results are supported by 
the literature. One study directly compared PSP and PD patients' neuropsychiatric 
features and showed that PSP patients exhibited more apathetic disturbances and PD 
patients more hallucinations (17). Several studies show that apathy frequently occurs in 
patients with specific tauopathies (27-30) and hallucinations in those with specific alpha-
synucleinopathies (15, 17,21,23), but none of the studies compared these two 
proteinopathies. 
Even at early disease stages, patients with tauopathies had more neuropsychiatric 
disturbances than those with alpha-synucleinopathies. This finding is supported by a 
study that showed PSP patients had significantly higher total NPI scores compared to PD 
patients (18). The published literature using the NPI to examine patients with tauopathies 
report average total NPI scores comparable to our data (18,27-30), thus our sample set is 
representative oftauopathy patients reported in past studies. On the other hand, current 
literature recording neuropsychiatric disturbances in patients with alpha-
synucleinopathies, report higher average NPI totals compared to our findings (15-19, 21-
14 
25, 36). One explanation for the differences with the literature is that our alpha-
synucleinopathy sample has a large proportion of PD patients, who show the least 
neuropsychiatric disturbances than the other alpha-synucleinopathy diseases (15-18). 
Moreover, in the previous studies, patients at later stages who exhibit more 
neuropsychiatric disturbances were included (15-18). Additionally, no studies have 
reported neuropsychiatric disturbances using the NPI in patients with MSA, an alpha-
synucleinopathy disease included in our sample. Thus, effects on the average NPI total 
are unknown. 
The patients with tauopathies had lower overall cognition levels than those with 
alpha-synucleinopathies. Our findings are supported by the literature (37-39). A study 
using the MMSE to examine cognitive differences in PSP, MSA, and PD patients showed 
that the mean score of the PSP patients was lower than that of MSA patients and that 
there were no significant cognitive differences between the PD and MSA patients (37). In 
a second study, cognition was assessed in atypical parkinsonian patients using four 
different tools including the MMSE. PSP and eBD patients exhibited significantly 
impaired cognitive abilities when compared to the controls and MSA patients (38). 
Our patients with tauopathies also had significantly more motor disturbances 
(UPDRS and UPDRS III scores) than patients with alpha-synucleinopathies. These 
results are also supported by the literature. A study comparing PD and PSP patients, 
showed that the total UPDRS score was higher for PSP patients compared to the PD 
patients (40). Furthermore, a second study examining the UPDRS III score in MSA, PSP, 
and PD patients showed that the average UPDRS III score was higher in PSP patients 
compared to MSA patients. On the other hand, it concluded that the UPDRS III score was 
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significantly higher in PD patients compared to PSP and MSA patients (37). However, in 
that study, the PD patients had a significantly longer disease duration compared to the 
PSP and MSA patients, and motor disturbances increase with disease progression, 
explaining the differences found (41, 42). 
Neuropsychiatric, cognition, and motor correlations: 
Our study confirmed that in the patients with tauopathies there are no correlations 
between neuropsychiatric, cognitive, and motor disturbances, suggesting that in the 
tauopathies the affected pathways degenerate independently. Prior studies using the NPI 
and MMSE in tauopathy patients found the same results (15, 18,28-30), showing no 
association between motor and cognitive functions. Similar to our findings, a study of 
CBD patients showed that the neuropsychiatric features were not associated with the 
motor scores, but found that the CBD patients with higher UPDRS scores also had higher 
MMSE scores, suggesting a relationship between cognitive and motor skills (28). On the 
other hand, a study in PSP patients found that the total UPDRS score was inversely 
related to the total MMSE score (29). A possible explanation of the difference in our 
results and those of the literature may be related to differences in disease stages (26, 27). 
Furthermore, patients with alpha-synuc1einopathies had a significant association 
between neuropsychiatric, cognitive and motor disturbances. Our results show that as the 
cognition worsens (or as the total MMSE score decreases), patients have increased 
neuropsychiatric disturbances. These findings are supported by a study that examined the 
relationship between cognitive and neuropsychiatric disturbances in PDD patients using 
the same assessment tools, and found that patients who scored below the median total 
MMSE had higher NPI scores (15). Two other studies found a relationship between the 
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total NPI score and the MMSE total in patients with alpha-synucleinopathies (17, 26). In 
addition, patients exhibiting more neuropsychiatric disturbances were more likely to have 
a motor decline. 
No previous studies have used the NPI and UPDRS to compare neuropsychiatric 
and motor disturbances in the patients with alpha-synucleinopathies, although there are 
two studies that support our findings using different instruments. The first supporting 
study shows a direct relationship between neuropsychiatric symptoms and motor 
disturbances in PD patients using the UPDRS I score to measure neuropsychiatric 
symptoms, and the UPDRS III score to measure motor symptoms (43). A second study 
that measured the neuropsychiatric disturbances in PD patients with the Hamilton rating 
Scale of Depression and Hamilton Anxiety Scale showed that these scores were 
correlated with the UPDRS III score (44). 
In addition, the MMSE score correlated with the total UPDRS score and UPDRS 
III score in the patients with alpha-synucleinopathies, showing that patients with more 
motor disturbances exhibit more cognitive disturbances. Our findings are supported by a 
study in DLB patients, which showed that patients who had MMSE scores less than 18 
had a higher total UPDRS score (26). Smilarly, a study in PD patients showed an inverse 
correlation between the MMSE score and the UPDRS III score (45). 
Exploring increases in hallucination and delusion disturbances: 
The presence and severity of the neuropsychiatric symptoms can affect a patient's quality 
of life (46), thus improvements of these symptoms are necessary. Psychotic symptoms, 
including delusions, hallucinations, and delirium, are typically observed in DLB and 
PDD, but would not occur in PD without medication treatment (47, 48) (49-54). Prior 
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studies showed that parkinsonian patients exhibiting psychosis had higher levodopa daily 
doses (51,54-57) and higher dopamine agonist daily dose (55-58) than those without 
psychosis. However, our study found no significant differences in the levodopa daily 
dose or dopamine agonist daily dose used in the patients with and without hallucinations. 
Additionally, there was no significant difference in the levodopa daily dose or dopamine 
agonist daily dose used in the patients with and without delusions. There are a few studies 
that failed to find a relationship between the levodopa daily dose and the occurrence of 
delusions and hallucinations (18, 43, 59-62). 
A review paper that reevaluated the frequency of psychotic symptoms and the 
doses of levodopa in studies conducted before 1998, suggests that the literature 
overestimated the relation between levodopa dose and psychotic adverse results (63). 
Causes of overestimation are related to different inclusion factors, classification of 
psychotic effects, and different levodopa dosages (48, 49). 
Our findings on the other hand are suggestive that delusions and hallucinations 
are not the results of dopaminergic medications, and may be associated with disease 
progression. Patients with hallucinations were significantly older when the NPI was 
administered and older at disease onset compared to patients without hallucinations. 
Additionally, older age at evaluation and disease onset was also recorded in the patients 
with delusions compared to the patients without delusions. Our results are supported by 
prior literature that shows that the frequency of delusion and hallucination disturbances 
increased in older patients (43, 48,64,65). A study reported that age at evaluation and 
age at onset ofPD were significantly associated with hallucinations. Hallucinations were 
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more frequent in PD patients with more than five year of disease duration and older age 
at evaluation (48). 
Caregiver distress: 
We found no significant differences in caregiver distress in caregivers of patients with 
tauopathies and those of patients with alpha-synucleinopathies. Additionally, this study 
found an association between caregiver distress and severity of neuropsychiatric 
disturbances when analyzing depression, apathy, anxiety, and nighttime domains only. 
Current literature supports our findings that severity of neuropsychiatric disturbances 
correlate significantly with caregiver distress using different measuring tools other than 
the NPI (66-68). One supporting study reported association of both the Hamilton 
depression score and anxiety scores of the patient with caregiver burden, thus showing a 
correlation between neuropsychiatric disturbances and caregiver distress (68). 
Associations with severity of symptoms should be cautiously interpreted because 
disturbances can fluctuate due to medication timing and degree of physical activity. Thus, 
caregiver distress can vary as well (69). 
In administering the NPI, we noticed that five caregivers (3 with tauopathies and 
2 with alpha-synucleinopathies) answered yes to the lead question regarding euphoria but 
did not answer positively to any of the subsequent questions. After reviewing the 
symptoms, we noted that 4 of the 5 patients were classified with pseudobulbar affect, 
which is an emotional disorder illustrated by uncontrollable laughing and crying outburst, 
reactions that do not reflect the patient's true feelings (70, 71). We did not use a 
standardized measuring tool for pseudobulbar affect, but this behavior was observed by 
the clinician. Other terms used to describe pseudobulbar affect are pathological laughing 
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and crying (71-74), emotional lability (72), emotional incontinence (72, 75), and 
emotionalism (72). Unexperienced clinicians should differentiate euphoria and 
depression from pseudobulbar affect, as treatments are specific and can improve patients 
and caregivers quality of life (70, 72, 73, 76-79). 
Limitations: 
One limitation in this study is that the NPI was administered by more than one trained 
personnel, potentially affecting the consistency of the methods. However, the NPI is an 
extremely structured measuring tool with high ratings of validity and reliability (12-14). 
Additionally, this study used two versions of the NPI to evaluate the 
neuropsychiatric symptoms of our sample. There are slight differences between the new 
and old versions, although, the variations do not affect the total NPI score and allow for 
advanced investigations. The new version assesses two additional behavioral domains 
including nighttime behavior and appetite/eating changes. Moreover, the newer NPI tool 
evaluates the caregiver distress caused by the occurrence of individual neuropsychiatric 
disturbances. 
Our entire patient sample was clinically diagnosed by three movement disorder 
specialist using established diagnostic criteria. Using clinical diagnosis is accurate 
although higher accuracy can only be achieved with pathological confirmation. Past 
studies report a high rate of misdiagnosis in parkinsonian patients (80-87). 
We analyzed in detail a subsample rather than the full sample to account for 
between-group differences in disease duration and age at NPI evaluation. Although it 
would seem better to include the whole patient sample, and ideal that both proteinopathy 
groups were matched for overall cognition and motor disturbances, we believe that 
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including the full sample would have biased our results as disease duration and age at 
evaluation influence the conclusions. 
This was a cross-sectional study observing a large number of patients; however, a 
longitudinal approach would yield a better understanding of the progression of the 
various neuropsychiatric features in the proteinopathies, as well as their relation with the 
treatment. 
Summary and future studies: 
This is the first study to assess neuropsychiatric disturbances to differentiate tauopathies 
and alpha-synucleinopathies. Our study included a relatively large sample with a variety 
of diseases, all presenting to one site for diagnosis and evaluation. This allows for a 
homogenous sample to analyze. Additionally, this study used valid and reliable 
instruments to assess the neuropsychiatric, cognitive, and motor disturbances and also 
assessed caregiver distress. 
Patients with tauopathies significantly exhibited more apathetic disturbances and 
patients with alpha-synucleinopathies significantly reported more hallucinations. Our 
results suggest that the presence of hallucinations and delusions are not related to 
dopaminergic medication alone, and are due to disease progression and especially due to 
differences in age. From our results, we can conclude that patients with tauopathies and 
alpha-synucleinopathies cannot be differentiated based on neuropsychiatric features 
alone, because of the overlapping disturbances. 
In the patients with alpha-synucleinopathies, the neuropsychiatric disturbances 
increased when the cognition and motor disturbances worsened. On the other hand, these 
associations were not observed in the patients with tauopathies. These findings suggest 
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that in patients with alpha-synucleinopathies motor, cognitive, and psychiatric pathways 
may degenerate in parallel. However, this is not the case for the tauopathies. Lastly, this 
study found no significant differences in caregiver distress between the two 
proteinopathy groups, but found that caregiver distress was related to the severity of 
neuropsychiatric disturbances. The use of the NPl in clinical practice could allow for 
treatment of neuropsychiatric symptoms and signs, thus improving the patient's quality of 
life and caregiver distress. 
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Table 1 
NPI sources published from 1996-2008 evaluating PD, PDD, DLB, PSP and CBD 
Parkinson's Parkinson's Dementia Progressive Corticobasal 
disease 1,2,3,4 disease with with Lewy Supranuclear degeneration 
Dementia 5 Body 6 Palsy 2,7-9 7,10 
NP[ Domain (n=43-139) (n=537) (n=100) (n=22-61) (n=15-20) 
Delusions 4.4-17% 24.6% 27% 0-3% 5-7%* 
Hallucination 8.9-26.6% 44% 18% 0-2% 0%* 
Agitation 12-22.4% 32.6% 48% 3-21% 20% 
Depression 34-68.9% 58% 38% 18-25% 70-73% 
Anxiety 16-68.8% 49% 46% 12-18% 13-15% 
Euphoria 0.7-12.8% 3.7% 5% 0% 0% 
Apathy 16.5-48.3% 54% 60% 82-91% 40% 
Disinhibition 6.5-11% 11.70% 20% 35-56% 12-15% 
Irritability 8-46.8% 29.70% 51% 9-20% 20% 
Aberrant 
Motor 
Behavior 4.7-13.4% 22% 30% 6-9% 7-15% 
Nighttime 
Behavior 44.2% N/A 32% N/A N/A 
Appetitel 
Eating 
Change 30.2% N/A 24% N/A N/A 
lAarsland D, et al. 1999,2 Aarsland D, et al. 2001, 3 Kulisevsky, el at. 2008,4 McKinlay A, et al. 2008, 5 Aarsland D, et al. 2007, 6 
Caputo M, et aL 2008, 7 Litvan I, et al. 1998, 8 Litvan I, et aL 1996, 9 Litvan I, et al. 1998, lO Cummings JL, et aL 2000 
* Delusions and hallucinations frequently occur in the patients with alpha-
synucleinopathies compared to the patients with tauopathies 
t No previous study has used the NPI to examine neuropsychiatric disturbances in MSA 
patients, an alpha-synucleinopathy disease 
NPI = Neuropsychiatric Inventory 





Demographics Mean± SD Range Mean± SD Range 
Age at NPI evaluation (years) 67.7 ± 7.3 53-85 69.4± 10.1 42-93 
Gender 27 MI 32 F 116M/57F 
Education (years) 14.8 ± 3.4 8-23 14.1 ±2.7 6-21 
Duration of symptoms (years) 2.9 ± 1.8 0-7 3 ±2.2 0-7 
MMSE score 25.3 ± 5.9 0-30 27.0 ± 6.3t 0-30 
Total UPDRS score 54.2± 18.5 16-111 37.5 ± 20.5t 3-116 
UPDRS III score 29.3 ± 12.5 4-84 21.8 ± 12.9t 0-69 
tp<O.OOI 
NPI = Neuropsychiatric Inventory 
MMSE = Mini-Mental State Examination 
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Table 3 











Aberrant Motor Behavior 
Nighttime Behavior 
Appetite! Eating Change 
Total NPI 
* p < 0.05 
t p < 0.001 
Tauopathy 
(N = 59) 
Mean± SD Frequency 
0.1 ± 0.3 6.8% 
0.1 ± 0.3 3.4% 
0.5 ± 1.1 18.6% 
2.1 ± 3.0 55.9% 
1.0 ± 2.2 27.1% 
0.1 ± 0.1 1.7% 
4.0± 3.8 67.8% 
0.9± 2.8 15.3% 
1.1±2.4 25.4% 
0.5 ± 2.1 8.5% 
2.4 ± 3.2 51.3% 
2.0 ± 3.1 43.6% 
10.3 ± 8.6 
NPI = Neuropsychiatric Inventory 
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Alpha-synucleinopathy 
(N = 176) 
Mean± SD Frequency 
0.2 ± 0.8 7.5% 
0.4 ± 0.9t 17.9% 
0.5 ± 1.4 16.2% 
1.6 ± 2.3 54.3% 
1.0 ± 2.0 32.4% 
O.O± 0.0 0.0% 
1.6 ± 2.7* 40.5% 
0.3 ± 1.5 8.7% 
0.4 ± 1.2 16.8% 
0.2 ± 1.2 5.8% 
2.2 ± 3.5 41.5% 
1.2±3.1 33.6% 
6.1 ± 7.5 
Table 4 
NPI Caregiver distress scores 
Tauopathy Alpha-synucleinopathy 
(N = 15) (N = 58) 
NPI Domain Mean± SD Range Mean± SD Range 
Delusions N/A N/A 3.2 ± 1.5 1-5 
Hallucinations N/A N/A 1.8± 1.7 0-4 
Agitation 4.0± 0.0 4 2.3 ± 1.5 0-4 
Depression 2.5 ± 1.1 1-5 2.1 ± 1.2 0-5 
Anxiety 1.6 ± 1.1 0-3 1.7± 1.4 0-5 
Euphoria N/A N/A N/A N/A 
Apathy 2.7 ± 1.2 1-5 2.4 ± 1.1 0-5 
Disinhibition 3.0± 0.0 3-3 1.0 ± 1.0 0-2 
Irritability 2.0 ± 1.4 0-4 1.9 ± 1.0 1-4 
Aberrant Motor Behavior N/A N/A N/A N/A 
Nighttime Behavior 1.8 ± 1.3 0-3 1.8 ± 1.2 0-5 
Appetitel Eating Change 0.6 ± 0.5 0-1 1.1 ± 1.2 0-4 
Total Caregiver Distress 7.9± 5.6 0-5 5.7 ± 5.3 0-5 
*Caregiver distress was recorded only when the patient exhibited a specific symptom. 
Caregivers rated their distress caused by the presence of the individual domain (0-5, no 
distress to very severe distress) 
NPI = Neuropsychiatric Inventory 
NI A = not applicable 
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